BARBARA ANN KARMANOS CANCER INSTITUTE

Barbara Ann Karmanos Cancer Institute, part of McLaren Health Care, is the first to offer the FDA-approved TheraBionic P1 device, using radiofrequencies to treat advanced liver cancer at home. The device, approved in September 2023, targets tumor-specific frequencies to block cancer cell growth without affecting healthy tissue.

A cancer specialist praises a foundation's efforts to increase diversity in clinical trials through scholarships and internships. Patients respond more positively to doctors of similar backgrounds, but barriers like lack of knowledge, access, and biases affect participation. Diversity in trials is crucial for accurate results, and initiatives like community engagement and education are key to overcoming these challenges.

DCTs are progressing from disillusionment to enlightenment, with key areas for improvement including data integration, patient diversity, regulatory harmonization, and long-term engagement. Oncology trials benefit from DCTs, reducing patient burden and enhancing accessibility. Site-level acceptance of DCT elements requires fair compensation, efficient training, and user-friendly interfaces. Collaboration, technology support, and proper resourcing are essential for DCT success. The future of DCTs lies in seamless integration with healthcare systems and optimizing patient experiences.

ESK981 + nivolumab showed no antitumor activity in AR+ mCRPC patients, with a maximum PSA decline of 14% and median rPFS of 3.7 months. The study was terminated due to futility.

Ataraxis AI emerges with $4M seed funding, unveiling Ataraxis Breast, a 30% more accurate AI-native breast cancer test. The company aims to develop AI-powered diagnostic tests for 50% of 2030's expected 26M cancer patients, transforming cancer care with personalized treatments.

Ataraxis AI launches with $4M seed funding, unveiling Ataraxis Breast, a 30% more accurate AI-native breast cancer diagnostic. Yann LeCun serves as AI advisor.

Nerissa Viola, Ph.D., won the 2024 Kales Endowment Faculty Award for her preclinical study on suppressing prostate cancer tumor growth using radiopharmaceutical therapy targeting TRA-1-60+ pluripotent stem cells, published in Theranostics.

Locations include Yale New Haven Hospital - Yale Cancer Center in Connecticut, Karmanos Cancer Institute in Michigan, University of Minnesota Medical School in Minnesota, Washington University School of Medicine in Missouri, Oncology Hematology Care Clinial Trials in Ohio, OU Health Stephenson Cancer Center in Oklahoma, Thomas Jefferson University in Pennsylvania, Sarah Cannon Research Institute (SCRI) - Nashville in Tennessee, and The University of Texas MD Anderson Cancer Center in Texas.